Eyenovia Inc
NASDAQ:EYEN

Watchlist Manager
Eyenovia Inc Logo
Eyenovia Inc
NASDAQ:EYEN
Watchlist
Price: 14.36 USD -9.23%
Market Cap: $41.4m

Operating Margin

-45 147.8%
Current
Improving
by 190 080.4%
vs 3-y average of -235 228.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-45 147.8%
=
Operating Income
$-30.3m
/
Revenue
$67.1k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-45 147.8%
=
Operating Income
$-30.3m
/
Revenue
$67.1k

Peer Comparison

Country Company Market Cap Operating
Margin
US
Eyenovia Inc
NASDAQ:EYEN
40.6m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.4B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.8B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

Lower than 99% of companies in the United States of America
Percentile
1st
Based on 14 112 companies
1st percentile
-45 147.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Eyenovia Inc
Glance View

Market Cap
41.4m USD
Industry
Pharmaceuticals

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2018-01-25. The firm is developing a pipeline of therapeutics based on its microdose array print (MAP) platform technology. Its pipeline is focused on the late-stage development of therapeutic indications for pediatric patients with progressive myopia in the United States and patients with age-related near vision impairment, or presbyopia indications. The firm is also developing the microdose fixed combination ophthalmic pharmaceutical for mydriasis. The firm's product candidates include MicroLine (for presbyopia), MicroPine (for progressive myopia) and Mydcombi (for mydriasis). MicroLine is its microdosed version of pilocarpine, an ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil. MicroPine is a topical treatment for progressive myopia, a back-of-the-eye disease. Mydcombi is a fixed combination micro-formulation product candidate for mydriasis (eye dilation).

EYEN Intrinsic Value
19.42 USD
Undervaluation 26%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-45 147.8%
=
Operating Income
$-30.3m
/
Revenue
$67.1k
What is Eyenovia Inc's current Operating Margin?

The current Operating Margin for Eyenovia Inc is -45 147.8%, which is above its 3-year median of -235 228.3%.

How has Operating Margin changed over time?

Over the last 3 years, Eyenovia Inc’s Operating Margin has decreased from -119.3% to -45 147.8%. During this period, it reached a low of -668 589.5% on Dec 31, 2023 and a high of -119.3% on Mar 3, 2022.

Back to Top